Arsenoplatin-1 (AP-1) is an innovative dual-action anticancer agent that contains a platinum(ii) center coordinated to an arsenous acid moiety. We found that AP-1 spontaneously aggregates in aqueous solutions generating oligomeric species of increasing length. Afterward, we succeeded in solving the crystal structure of the adduct formed between the model protein lysozyme and an early AP-1 oligomer that turned out to be a trimer. Remarkably, this crystal structure traps an early stage of AP-1 aggregation offering detailed insight into the molecular process of the oligomer's growth.
The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct / Ferraro, G.; Cirri, D.; Marzo, T.; Pratesi, A.; Messori, L.; Merlino, A.. - In: DALTON TRANSACTIONS. - ISSN 1477-9226. - 50:1(2021), pp. 68-71. [10.1039/d0dt04068a]
The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct
Ferraro G.;Merlino A.
2021
Abstract
Arsenoplatin-1 (AP-1) is an innovative dual-action anticancer agent that contains a platinum(ii) center coordinated to an arsenous acid moiety. We found that AP-1 spontaneously aggregates in aqueous solutions generating oligomeric species of increasing length. Afterward, we succeeded in solving the crystal structure of the adduct formed between the model protein lysozyme and an early AP-1 oligomer that turned out to be a trimer. Remarkably, this crystal structure traps an early stage of AP-1 aggregation offering detailed insight into the molecular process of the oligomer's growth.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.